RUBIUS THERAPEUTICS INC (RUBY)
US78116T1034 - Common Stock
RUBIUS THERAPEUTICS INC
NASDAQ:RUBY (3/6/2023, 7:00:03 PM)
After market: 0.0899 +0.01 (+8.31%)0.083
-0.04 (-33.55%)
Company Profile
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company is headquartered in Foxboro, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2018-07-18. The firm is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. The company develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its RTX-321 is an allogeneic artificial antigen presenting cell (aAPC) product candidate, which is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.
Company Info
RUBIUS THERAPEUTICS INC
C/O Verdolino & Lowey, P.C., 124 Washington Street, Suite 101
FOXBORO MASSACHUSETTS 02139
P: 16176799600.0
CEO: Pablo J. Cagnoni
Employees: 9
Website: https://www.rubiustx.com/
RUBY News
a year ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off Friday morning with a breakdown of the biggest pre-market stock movers traders need to keep an eye on!
a year ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off Monday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on!
a year ago - Seeking AlphaRUBY stock jumps on plan for liquidation (NASDAQ:RUBY)Rubius Therapeutics (RUBY) jumped ~10% pre-market Wednesday after announcing a plan for liquidation and dissolution subject to shareholder approval. Read the full stoy here.
a year ago - InvestorPlaceWhy Is T2 Biosystems (TTOO) Stock Down 21% Today?T2 Biosystems (TTOO) stock is falling hard on Tuesday as investors react to a proposed public offering from the company.
a year ago - InvestorPlaceWhy Is Atreca (BCEL) Stock Up Today?Atreca (BCEL) stock is getting a boost on Tuesday as the biopharmaceutical company continues a recent rally connected to insider buying.
RUBY Twits
Here you can normally see the latest stock twits on RUBY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
